Placental Histology and Its Critical Role in Recurrent Pregnancy Loss

When pregnancy ends in loss, parents often search for answers. Placental histology, the microscopic examination of placental tissue after delivery, can provide those answers in ways that few other investigations can. For couples experiencing recurrent pregnancy loss, defined locally as two or more losses before 20 weeks, examining what went wrong at the interface between mother and baby frequently uncovers treatable pathology. Pathologists at tertiary centres such as the Royal Women's Hospital in Melbourne routinely receive placentas from bereaved parents, and their reports often reshape clinical decisions for the next conception.

Across Australia, perinatal pathologists work closely with obstetric teams at tertiary maternity hospitals in Sydney, Brisbane, Adelaide, and Perth. The work has reshaped counselling for thousands of couples since the Amsterdam Consensus Statement on placental pathology was adopted locally. Many Australian units now follow the diagnostic categories outlined in that framework, and patients referred to recurrent pregnancy loss clinics at places like King Edward Memorial Hospital often have placental histology included as part of their workup.

Why Placental Histology Demands More Attention

The placenta is a transient organ that sustains the pregnancy for the entire duration of gestation. When it fails, the consequences are immediate and devastating. Placentas from pregnancy losses are submitted for histopathological examination in fewer than half of cases nationally, according to research published through the Stillbirth Centre of Research Excellence. Many clinicians still consider the examination unnecessary, particularly when the loss occurs early, but that view is slowly shifting.

The shift has been driven by evidence. Studies have linked specific placental lesions to subsequent pregnancy complications, including pre-eclampsia, fetal growth restriction, and recurrent loss itself. When a placenta is examined and a clear lesion identified, the couple gains a tangible explanation and clinicians gain a target for intervention. When the placenta is not examined, the next pregnancy is often managed as if nothing has been learned, leaving families without closure and obstetricians without a roadmap.

Australian pathologists use a standardised reporting system based on the Amsterdam criteria, which divides lesions into maternal vascular, fetal vascular, and inflammatory categories. This system has been embraced by the Perinatal Society of Australia and New Zealand and is taught through training programs at the Royal College of Pathologists of Australasia.

Common Histopathological Findings in Recurrent Loss

Maternal vascular malperfusion is among the most frequently reported findings in recurrent pregnancy loss. It describes a constellation of features, including distal villous hypoplasia, accelerated villous maturation, and atherosis of spiral arteries. These changes reflect inadequate remodelling of the maternal vessels supplying the placenta, and they are particularly common in women with underlying hypertension, antiphospholipid syndrome, or thrombophilia. In an Australian cohort studied at the Mercy Hospital for Women, maternal vascular lesions accounted for a substantial proportion of recurrent losses in the second trimester.

Chronic histiocytic intervillositis is a rarer but striking lesion. It involves infiltration of the intervillous space by maternal histiocytes and is strongly associated with adverse outcomes, including recurrent loss and severe growth restriction. The condition is sometimes responsive to immunosuppression in subsequent pregnancies, though evidence remains limited. Massive perivillous fibrinoid deposition can recur across pregnancies and carries a similarly poor outlook.

Fetal vascular malperfusion, including fetal thrombotic vasculopathy and delayed villous maturation, points to problems in the fetal circulation rather than the maternal supply. These lesions are sometimes linked to inherited thrombophilias, cardiac anomalies, or umbilical cord abnormalities. When such lesions are identified, clinicians often extend their investigation to include fetal imaging, including fetal echocardiography indications and interpretation, which can reveal structural cardiac causes for impaired placental perfusion.

Building a Diagnostic Pathway for Australian Couples

The pathway from loss to diagnosis in Australia is often fragmented. A woman experiencing her second miscarriage might see her GP, then a general obstetrician, then a fertility specialist, and only later reach a recurrent pregnancy loss clinic at a tertiary centre. Each handoff can mean that the placenta from the most recent loss has already been discarded by the pathology laboratory, simply because it was not requested at the time.

Specialists at the Royal Hospital for Women in Sydney and the Mater Mother's Hospital in Brisbane have begun advocating for routine placental submission after every second-trimester loss. The message to patients is straightforward: ask your obstetrician or midwife to ensure the placenta is sent to pathology. Many Australian laboratories offer this service through Medicare, although out-of-pocket costs can apply for parents who engage a perinatal pathologist privately.

Once histology is completed, the report feeds into a broader investigation that typically includes karyotyping of products of conception, antiphospholipid antibody screening, thrombophilia testing, and detailed pelvic ultrasound. For couples in regional and remote areas, telehealth consultations with metropolitan specialists have made multidisciplinary workup more accessible. Families in the Northern Territory or far western New South Wales sometimes wait weeks for results to return from the nearest tertiary laboratory.

When Pathology Guides Treatment

Identifying a specific lesion can change clinical management. Maternal vascular malperfusion findings often prompt initiation of low-dose aspirin in subsequent pregnancies, a therapy that has solid evidence behind it in women at risk of pre-eclampsia. In some Australian clinics, aspirin is started even before conception once the lesion is documented. Heparin is sometimes added for women with antiphospholipid syndrome, although evidence for heparin in unexplained recurrent loss remains contested.

Inflammatory lesions, particularly chronic histiocytic intervillositis, may respond to combinations of prednisolone, hydroxychloroquine, or intravenous immunoglobulin in subsequent pregnancies. These interventions are usually managed by maternal-fetal medicine specialists at tertiary centres and require careful counselling because the evidence base is small. Couples considering such treatment are often referred to specialist clinics where research protocols are active, including collaborative studies coordinated through FAOPS 2020.

Fetal vascular lesions may prompt surveillance for fetal growth restriction through serial ultrasounds from 24 weeks onwards, alongside doppler studies of the umbilical artery. When recurrent fetal vascular malperfusion is identified and a fetal cardiac cause is suspected, detailed echocardiography becomes part of the surveillance plan. Some Australian units offer fetal cardiac assessment through their maternal-fetal medicine service, shortening waiting times considerably.

Australian Research and International Collaboration

Australian researchers have made substantial contributions to the international understanding of placental pathology. The Stillbirth Centre of Research Excellence, headquartered in Brisbane, has run several large studies linking placental findings to stillbirth and recurrent loss. Researchers at the University of Melbourne and Monash University have contributed to international consensus work, including refinements to the Amsterdam criteria.

Collaboration extends across the Asia-Oceania region, with perinatal pathologists meeting regularly at congresses supported by organisations such as the Federation of Asian and Oceania Perinatal Societies. These meetings allow clinicians to compare diagnostic approaches and share challenging cases. Local research funding, including from the National Health and Medical Research Council, has supported projects examining how placental inflammation relates to subsequent pregnancy outcomes, fair dinkum work that often goes unrecognised outside specialist circles.

Practical Advice for Couples Moving Forward

After a pregnancy loss, parents frequently feel a lack of control. Pursuing placental histology can restore some of that control by generating information. Request that your obstetrician or midwife submits the placenta for examination, even if the loss occurred at home. If you delivered in a tertiary centre, the pathology department should automatically receive the specimen; if you delivered elsewhere, ask explicitly.

Ask your specialist about which findings in your placental report might guide treatment in the next pregnancy. Keep a copy of the report and bring it to every subsequent appointment. Consider joining a support organisation such as the Pink Elephants Support Network or Sands Australia, which provides peer support alongside evidence-based resources.

Steps worth taking with your care team:

• Submission of placental tissue to a pathology lab experienced in perinatal work
• Karyotyping of products of conception when histology suggests fetal pathology
• A follow-up appointment to discuss the histology report in plain language
• Referral to a recurrent pregnancy loss clinic after two or more losses

Questions to raise with your specialist:

• What category of lesion was found, and how confident are you in the diagnosis?
• Is there an association with my own health conditions or medications?
• Should we modify our conception plan, including the timing of a subsequent pregnancy?
• Are there clinical trials in Australia that might be appropriate for us?

Comparison of Placental Lesion Categories

Moving Forward After Pathology Results

The weeks after a pathology report arrives can feel strange. There is relief at having an answer and grief at the same time, especially when the lesion identified carries a poor prognosis for future pregnancies. Australian bereavement midwives and clinical psychologists are embedded in most tertiary maternity services and can help families process what the report means, both medically and emotionally.

Specialist recurrent pregnancy loss clinics operate in every Australian state, generally requiring a referral from a GP or obstetrician. Waiting times vary, with some clinics in Perth and Adelaide booking several months ahead. Private fertility specialists can often expedite parts of the workup, although the placental histology must still come from the original loss. If you have placental tissue archived from a previous loss, ask whether retrospective review is possible; some pathology laboratories will retrieve archived specimens for a fee.

The value of placental histology lies in the conversation it enables. With a clear diagnosis, couples and clinicians can plan together rather than guess. Gather what you can, ask for placental review, and bring your questions to your next appointment. Your obstetrician, midwife, and pathologist are there to help you make sense of what the placenta can tell you about your next pregnancy.